Navigation Links
Chemir Announces New Custom Synthesis Laboratory
Date:2/14/2013

St. Louis, Missouri (PRWEB) February 14, 2013

Chemir is proud to announce the opening of its new chemical synthesis laboratory. The recently renovated space expands the company’s capability to synthesize analytical standards and pharmaceutical intermediates, as well as provide process development and litigation support.

The new lab boosts the efficiency of Chemir’s team of Ph.D., M.S. and B.S. synthetic chemists, as they provide organic synthesis of compounds at the milligram to kilogram scale. The dedicated laboratory space, designed by the chemists, contains new hoods, new countertops, and updated utilities. The newly installed hoods offer greater volume and expanded utilities, expanding the range of possible reactions. The renovation is part of an extensive building improvement plan for Chemir in 2013.

The expanded organic synthesis lab also reflects a greater demand for these services to support legal challenges, including patent prosecution and infringement defense.

“We’ve worked on legal synthesis projects for a variety of cases and industries,” says Dr. Albert Lee, Senior Manager of Custom Synthesis. “For example, we supported a patent prosecution case by performing synthesis based on technology from the early 1990s. We’ve also supported infringement defense issues by synthesizing a necessary analytical standard when the opposing side was uncooperative and would not provide it.”

Chemir’s custom synthesis team was previously known as IQsynthesis and Gateway Chemical Technology. Established in 1995, the group moved to the Chemir location in 2010 and assists the pharmaceutical, agrichemical and specialty chemical industries in the early phase production of molecules for research and development. The group also provides custom synthesis services for litigation support.

About Chemir –A Division of Evans Analytical Group
Chemir provides scientific solutions with analytical services, product development and litigation support services. Since 1959 this independent laboratory has solved thousands of issues involving deformulation (reverse engineering), contaminant and impurity identification, failure analysis, analytical method development, product development, custom synthesis, patent, intellectual property, and other legal challenges for over 7000 clients. The scientific staff of 35, including 8 Ph.D. level chemists, uses state-of-the-art analytical instrumentation and expert interpretations to assist such industries as polymers, plastics, medical devices, pharmaceuticals, packaging, coatings, food and beverages, personal care products, consumer products, specialty chemicals, industrial products and more. For more information, visit http://www.chemir.com.

Read the full story at http://www.prweb.com/releases/Synthesis/Laboratory/prweb10431173.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , February 8, 2016 ... ("Atlas Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) molecular ... CE Mark its Chlamydia trachomatis (CT) test to be launched ... the IVD Directive (98/79/EC), the CT test is now cleared ... --> The launch of the io® CT ...
(Date:2/6/2016)... ... February 06, 2016 , ... Contact:, Abby Mitchell, ... Excellence in Education Sponsors Teacher Training Program , Bite of Science Dinner Event ... Center for Excellence in Education (CEE) will sponsor a Bite of Science professional ...
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical industry ... a host of launch activities including the identification and ... launch activity is especially high in the oncology therapeutic ... Best Practices and the Role of Medical Affairs in ... focused on oncology therapies find better ways to utilize ...
(Date:2/5/2016)... February 5, 2016 Amarantus BioScience ... company focused on developing products for Regenerative Medicine, Neurology ... Pediatric Disease Designation (RPDD) from the US Food and ... MANF. MANF was previously granted orphan drug designation (ODD) ... Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... fourth quarter of 2014. Gross margin was 46% (32). ... Earnings per share increased to SEK 6.39 (loss: 0.49). Cash ... --> --> January to December ... 1,142% compared with 2014. Gross margin was 43% (31). ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... Potentials of that Rising Market Are you ... new analysis forecasts revenues for checkpoint inhibitors. Visiongain,s ... world market, submarket, product and national level. ... Instead discover what progress, opportunities and revenues those ...
Breaking Biology News(10 mins):